Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas

NCT04848064 is registered in ClinicalTrials.gov with John Reneau as lead sponsor.

NCT NCT04848064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04848064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas
Lead sponsor
John Reneau
Phase
Phase 1
Overall status
Recruiting
Start date
May 6, 2022
Completion date
January 30, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent adult t-cell leukemia/lymphoma, recurrent primary cutaneous t-cell non-hodgkin lymphoma, refractory adult t-cell leukemia/lymphoma, refractory primary cutaneous t-cell non-hodgkin lymphoma